Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EUT6 | ISIN: VGG1466B1452 | Ticker-Symbol:
Branche
Telekom
Aktienmarkt
Sonstige
1-Jahres-Chart
BORQS TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
BORQS TECHNOLOGIES INC 5-Tage-Chart
GlobeNewswire (Europe)
136 Leser
Artikel bewerten:
(0)

Borqs Technologies, Inc.: Borqs Technologies Reports Half-Year 2024 Financial Results; Successfully Increases Efficiency

Finanznachrichten News

SANTA CLARA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Borqs Technologies, Inc. (U.S. OTC: BRQSF, "Borqs" or the "Company"), a global provider of embedded software and products for the Internet of Things (IoT), today announced its financial results for the first half of 2024. Interim financial statements were filed today with the SEC.

First-Half 2024 Financial Highlights

For the six months ended June 30,
20242023vs. H1 2023
Revenues ($K)16,77314,992+ 11.9%
Gross Margin20.2%19.4%Up 0.8%
Operating expenses ($K)7,08211,996- 41.0%
Net income (loss) from operations15,023-28,801n/a

For the six months ended June 30, 2024, Borqs reported total net revenues of US$16.77 million, reflecting an increase from US$14.99 million in the same period of 2023, an increase of 11.9%, driven by strong performances in both software and hardware segments. The Company achieved a total gross profit of US$3.39 million, up from US$2.91 million in the prior year. This positive performance underscores our commitment to operational efficiency, with total operating expenses decreasing significantly to US$7.08 million from US$12 million from the same period last year, primarily due to a reduction in general and administrative expenses.

As a result of these strategic initiatives and the completed sale of the Company's interests in the solar subsidiary, Borqs recorded a net income of US$15.02 million from operations for the first half of 2024, a remarkable turnaround from a net loss of US$28.80 million in the same period of the previous year. This notable improvement has been supported by gains realized from the disposal of subsidiary interests and the cancellation of shares related to the former subsidiary.

"Our H1 results highlight the significant progress we are making in executing our recently outlined capital structure revamp," said Pat Chan, Chairman & CEO of Borqs. "The strategic actions we implemented in the first half of this year position us for improved profitability and enhanced liquidity going forward. We are encouraged by the positive underlying trends that these results reflect."

About Borqs Technologies, Inc.
Borqs Technologies is a global leader in software and products for the IoT, providing customizable, differentiated and scalable Android-based smart connected devices and cloud service solutions. Borqs has achieved leadership and customer recognition as an innovative end-to-end IoT solutions provider leveraging its strategic chipset partner relationships as well as its broad software and IP portfolio. Borqs' unique strengths include its Android and Android Wear Licenses which enabled the Company to develop a software IP library covering chipset software, Android enhancements, domain specific usage and system performance optimization, suitable for large and low volume customized products.

Investor relations contact:
E: IR@borqs.com

Disclaimer on Forward Looking Statements:
Certain statements in this release are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements due to risks or uncertainties associated with our expectations. Words such as "expects", "believes", "anticipates", "intends", "estimates", "predicts", "seeks", "may", "might", "plan", "possible", "should" and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements relate to future events or future results, based on currently available information and reflect our management's current beliefs. Many factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking statements, including the possibility that the positive trends as described herein may not continue, and the previously announced contemplated transactions between Borqs and Sasken Technologies, Inc. may not be consummated as described, or at all, and that the positive benefits of the transactions, stock buy-back and the future investment possibilities may not transpire as described or at all. The reader is advised to refer to both companies' filings with their respective securities and exchange authorities for additional information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements. Except as expressly required by applicable securities law and other regulatory requirements, the companies disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.